Semaglutide vs Mounjaro for Weight Loss UK Comparison

Last updated: March 2026

When it comes to weight loss medications, semaglutide and Mounjaro (tirzepatide) have been making waves across the UK—and honestly, I’ve been fielding more questions on these two than anything else lately. Both are injectable drugs originally developed for type 2 diabetes but now widely prescribed off-label or approved for weight management. But which one truly edges out the other for shedding pounds? From doses to side effects, availability to effectiveness, I’ve sifted through the latest research (including data from the 2023 SURPASS and STEP trials), NHS guidelines, and patient feedback to give you a clear, no-nonsense comparison. So, whether you’re exploring prescription options or just curious, here’s what I’ve found about Semaglutide vs Mounjaro for weight loss in the UK.

How Semaglutide and Mounjaro Work: A Quick Science Lesson

Both semaglutide and Mounjaro belong to a class of drugs called incretin mimetics, but their mechanisms aren’t identical. Semaglutide is a GLP-1 receptor agonist, which means it mimics the glucagon-like peptide-1 hormone. This hormone helps regulate appetite, insulin secretion, and digestion speed. In practical terms, it curbs hunger, making it easier to eat less without feeling deprived.

Mounjaro (generic name tirzepatide), on the other hand, is a dual agonist—targeting both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This combo approach aims to amplify weight loss and blood sugar control. Studies like the SURPASS series have shown that tirzepatide can lead to impressive weight reductions, often surpassing semaglutide in head-to-head trials.

Now here’s the thing: while both drugs boost insulin sensitivity and reduce appetite, Mounjaro’s dual action might provide a slight edge in weight loss, but it may also bring a different side effect profile. It’s a bit like comparing two sprints—one is steady and reliable (semaglutide), the other is potentially faster but with more twists (Mounjaro).

Effectiveness for Weight Loss: Looking at the Numbers

The data suggests both drugs are effective, but the degree and speed of weight loss differ somewhat. For semaglutide, the STEP 1 trial published in The New England Journal of Medicine (2021) found that participants lost roughly 14.9% of their body weight over 68 weeks on a 2.4mg weekly dose. That’s seriously impressive when you consider that typical lifestyle changes often yield 5-10% loss.

Mounjaro’s results, particularly from SURPASS-2 (2023), showed even more weight loss at higher doses—up to 20.9% body weight reduction over 72 weeks with a 15mg weekly dose. That’s roughly 5-6 kg more than semaglutide on average.

However, the higher doses also tend to come with more intense side effects, which can affect tolerability. Plus, Mounjaro’s weight loss seems to kick in faster, but maintaining it long-term still requires lifestyle adjustments.

So what does this actually mean? If you’re aiming for maximum pounds off and don’t mind a bit of trial and error with side effects, Mounjaro might be worth discussing with your doctor. But if you want a well-tested, slightly gentler approach, semaglutide is a solid bet.

Dosage and Administration in the UK

Dosage for both drugs is patient-specific and titrated carefully to balance effectiveness and tolerability. With semaglutide (marketed in the UK as Wegovy for weight loss), the starting dose is generally 0.25mg once weekly, gradually increasing over 16-20 weeks to a maintenance dose of 2.4mg weekly. This slow ramp-up helps minimise gastrointestinal side effects such as nausea or diarrhoea.

Mounjaro’s dosing starts at 2.5mg weekly and is increased every 4 weeks by 2.5mg increments, up to a maximum of 15mg weekly. The titration period is shorter than semaglutide’s, but some patients report more intense nausea and stomach upset during the early stages.

Both drugs come as subcutaneous injections, typically administered in the thigh, abdomen, or upper arm. In my experience, many patients find it manageable with a pen injector similar to insulin pens.

Remember: never adjust doses without consulting a healthcare professional. If you want practical help starting semaglutide, check out my guide on Understanding Semaglutide Dosage for Weight Loss Beginners.

Side Effects and Safety: What UK Users Should Know

Side effects are a big reason why people hesitate with these drugs. Both semaglutide and Mounjaro commonly cause nausea, vomiting, diarrhoea, and constipation—usually temporary and easing after a few weeks. In the UK, most prescribing guidelines recommend a slow dose escalation to reduce these issues.

Less common but more serious risks include pancreatitis, gallbladder problems, and potential thyroid C-cell tumours (noted in animal studies). Neither drug is recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Honestly, some folks find Mounjaro’s dual action means side effects can hit harder and last longer, but it varies widely. Overall, both have good safety profiles when used correctly. The NHS requires prescription and monitoring, which helps manage risks effectively.

Note: Semaglutide is approved by NICE for certain obesity patients on the NHS, but Mounjaro is still mainly limited to type 2 diabetes management, making access a bit trickier. You can learn more about navigating access on the NHS with resources like Accessing Semaglutide on the NHS in 2026.

UK Availability and Cost Considerations

Currently, semaglutide is more widely available for weight loss in the UK, especially since NICE approved it back in mid-2023 for adults with a BMI over 30 or 27 with weight-related conditions. You’ll find the Wegovy brand or generic semaglutide through NHS prescriptions, though demand is high and waiting lists exist.

Mounjaro, branded as Mounjaro or tirzepatide, is mostly prescribed for type 2 diabetes in the UK. Off-label or private prescriptions for weight loss are possible but less common and often pricier. Weekly costs can range from £250 to £350 privately compared to £30-50 for semaglutide if covered on the NHS.

For those exploring alternatives, Where to Find Affordable Semaglutide in the UK is a helpful read, but do be cautious and consult your doctor first.

Comparison Table: Semaglutide vs Mounjaro for Weight Loss in the UK

Feature	Semaglutide	Mounjaro (Tirzepatide)
Mechanism	GLP-1 receptor agonist	Dual GLP-1 and GIP receptor agonist
Typical Weight Loss	Up to ~15% body weight (STEP trials)	Up to ~21% body weight (SURPASS trials)
Dosing	0.25mg to 2.4mg weekly (titrated over 16-20 weeks)	2.5mg to 15mg weekly (titrated every 4 weeks)
Side Effects	Nausea, vomiting, diarrhoea; usually mild	Similar but sometimes more intense GI effects
UK Approval for Weight Loss	Yes, NICE approved for obesity (BMI >30 or 27+ with conditions)	No official UK weight loss indication; diabetes only
Cost on NHS	Available on NHS for eligible patients	Not routinely available for weight loss on NHS

FAQs about Semaglutide vs Mounjaro for Weight Loss in the UK

Final Thoughts

So, wrapping this up—Semaglutide vs Mounjaro for weight loss in the UK boils down to a few key points: semaglutide is well-established, NHS-approved, and generally easier to access; Mounjaro offers potentially greater weight loss but is still primarily a diabetes drug and less accessible for obesity treatment here. Both require patience, proper dosing, and lifestyle tweaks to work well.

In my experience working with patients, semaglutide tends to be the safer and more reliable starting point for most. But if you’re curious about the newer Mounjaro and can afford private prescriptions, it might be worth a chat with your GP or specialist. Regardless of choice, always prioritise medical advice and monitoring—these drugs aren’t magic bullets, just powerful tools in the weight loss toolbox.

For detailed comparisons involving PCOS and other conditions, take a look at our article on Semaglutide vs Tirzepatide: Which is Better for PCOS-Related Weight Loss?.

For further scientific details, the NEJM STEP trial publication is a solid, trustworthy source.